Risk factors
Rallybio (RLYB) risk factors
Item 1A of every Rallybio Corp. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors78 risks28 new13 dropped14 reworded
Rallybio added 28 risks driven almost entirely by its proposed merger with Candid. The company faces severe dilution and retained only 14 employees.
Filed Mar 16, 2026 - FY2024 10-K risk factors63 risks
Rallybio relies heavily on early-stage candidates RLYB212 for FNAIT and RLYB116, operating with a small team of 25 employees. The company faces significant dilution risks due to a lack of committed external funds and no commercial revenue history. Strict healthcare regulations, intellectual property hurdles, and heavy reliance on third-party manufacturers and clinical sites dominate the risk profile.
Filed Mar 13, 2025